Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial

the NEXUS Study Group, for; C. Taylor, Peter; Saurigny, Didier; Vencovský, Jiří; Takeuchi, Tsutomu; Nakamura, Tadashi; Matsievskaia, Galina; Hunt, Barbara; E. Wagner, Thomas; Souberbielle, Bernard

doi:10.1186/s13075-019-1879-x

Public

Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial

Published in Arthritis Research & Therapy • Apr 18, 2019

Authors:

for the NEXUS Study Group

Peter C. Taylor

Didier Saurigny

Abstract

BACKGROUND: Namilumab (AMG203), an immunoglobulin G1 monoclonal antibody that binds with high affinity to granulocyte-macrophage colony-stimulating factor (GM-CSF), was evaluated in a phase II randomized, double-blind, placebo-controlled study to investigate the efficacy and safety in patients with ...

Subject

Medicine

Rheumatoid arthritis

Tolerability

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!